These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 8441174

  • 21. Effect of urinary trypsin inhibitor on osteoarthritis.
    Matsuo O, Tanaka S, Kikuchi H.
    Thromb Res; 1988 Nov 01; 52(3):237-45. PubMed ID: 3143165
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Interleukin-1 beta, plasminogen activator and inhibitor of plasminogen activator in synovial fluid of rheumatoid arthritis, psoriatic arthritis and osteoarthritis.
    Pianon M, Punzi L, Stefani MP, Bertazzolo N, Michelotto M, Finco B, Gambari PF.
    Agents Actions; 1994 Mar 01; 41(1-2):88-9. PubMed ID: 8079828
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy.
    Estellés A, Gilabert J, Andrés C, España F, Aznar J.
    Thromb Haemost; 1990 Oct 22; 64(2):281-5. PubMed ID: 2125378
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
    Casslén B, Bossmar T, Lecander I, Astedt B.
    Eur J Cancer; 1994 Oct 22; 30A(9):1302-9. PubMed ID: 7999418
    [Abstract] [Full Text] [Related]

  • 28. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis.
    Manicourt DH, Poilvache P, Van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ.
    Arthritis Rheum; 2000 Feb 22; 43(2):281-8. PubMed ID: 10693867
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis.
    Guiducci S, Del Rosso A, Cinelli M, Perfetto F, Livi R, Rossi A, Gabrielli A, Giacomelli R, Iori N, Fibbi G, Del Rosso M, Cerinic MM.
    Arthritis Res Ther; 2005 Feb 22; 7(6):R1244-53. PubMed ID: 16277677
    [Abstract] [Full Text] [Related]

  • 32. Rheumatoid synovial fluid contains bioactive leukemia inhibitory factor with cartilage degrading activity--another target for chondroprotective intervention.
    Bell MC, Carroll GJ.
    J Rheumatol; 2000 Feb 22; 27(2):332-8. PubMed ID: 10685793
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Localization of plasminogen activators and plasminogen-activator inhibitors in human gingival tissues demonstrated by immunohistochemistry and in situ hybridization.
    Kinnby B, Lindberg P, Lecander I, Matsson L.
    Arch Oral Biol; 1999 Dec 22; 44(12):1027-34. PubMed ID: 10669081
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
    Lockwood CJ, Krikun G, Papp C, Aigner S, Schatz F.
    J Clin Endocrinol Metab; 1995 Apr 22; 80(4):1100-5. PubMed ID: 7714076
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.